Tiziana Life Sciences plc: PDMR Dealing Tiziana Life Sciences plc: PDMR Dealing
LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq:…
Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215
Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of the Polθ…
MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis
GHENT, Belgium, Sept. 28, 2021 (GLOBE NEWSWIRE) — MRM Health, a biopharmaceutical company developing next-generation…
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate High…
Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)
REGULATED INFORMATION Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines,…
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Saint-Herblain (France) and New York (United States), September 28, 2021 – Valneva SE (Nasdaq: VALN;…
22nd Century to Participate in September and October 2021 Investor Conferences
BUFFALO, N.Y., Sept. 27, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
— Additional ~$19M Funding for Expanded Anthrax PEP Development Program — BARDA Contract Now Valued…
NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…